Al-Rasheed, N.M., Al-Rasheed, N.M., Hasan, I.H., Al-Amin, M.A., Al-Ajmi, H.N., Mohamad, R.A. & Mahmoud, A.M. (2017) Simvastatin Ameliorates Diabetic Cardiomyopathy by Attenuating Oxidative Stress and Inflammation in Rats. Oxid Med Cell Longev, 2017, 1092015.
Arango, C., Giraldez, M., Merchan-Naranjo, J., Baeza, I., Castro-Fornieles, J., Alda, J.A., Martinez-Cantarero, C., Moreno, C., de Andres, P., Cuerda, C., de la Serna, E., Correll, C.U., Fraguas, D. & Parellada, M. (2014) Second-generation antipsychotic use in children and adolescents: a six-month prospective cohort study in drug-naive patients. J Am Acad Child Adolesc Psychiatry, 53, 1179-1190,1190 e1171-1174.
Brondani, L.A., Assmann, T.S., Duarte, G.C., Gross, J.L., Canani, L.H. & Crispim, D. (2012) The role of the uncoupling protein 1 (UCP1) on the development of obesity and type 2 diabetes mellitus. Arq Bras Endocrinol Metabol, 56, 215-225.
Choi, S., DiSilvio, B., Unangst, J. & Fernstrom, J.D. (2007) Effect of chronic infusion of olanzapine and clozapine on food intake and body weight gain in male and female rats. Life Sci, 81, 1024-1030.
Correll, C.U., Penzner, J.B., Parikh, U.H., Mughal, T., Javed, T., Carbon, M. & Malhotra, A.K. (2006) Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child Adolesc Psychiatr Clin N Am, 15, 177-206.
De Hert, M., Kalnicka, D., van Winkel, R., Wampers, M., Hanssens, L., Van Eyck, D., Scheen, A. & Peuskens, J. (2006) Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry, 67, 1889-1896.
De Santis, M., Lian, J., Huang, X.F. & Deng, C. (2016) Early antipsychotic treatment in childhood/adolescent period has long-term effects on depressive-like, anxiety-like and locomotor behaviours in adult rats. J Psychopharmacol, 30, 204-214.
Deng, C. (2013) Effects of antipsychotic medications on appetite, weight, and insulin resistance. Endocrinol Metab Clin North Am, 42, 545-563.
Deng, C., Lian, J., Pai, N. & Huang, X.F. (2012) Reducing olanzapine-induced weight gain side effect by using betahistine: a study in the rat model. J Psychopharmacol, 26, 1271-1279.
Dori, N. & Green, T. (2011) [The metabolic syndrome and antipsychotics in children and adolescents]. Harefuah, 150, 791-796, 814, 813.
FDA (2005) Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. http://www.fda.gov/cder/guidance/index.htm.
Fedorenko, A., Lishko, P.V. & Kirichok, Y. (2012) Mechanism of fatty-acid-dependent UCP1 uncoupling in brown fat mitochondria. Cell, 151, 400-413.
Franco, J.M., Vallabhajosyula, S. & Griffin, T.J. (2015) Quetiapine-induced hypertriglyceridaemia causing acute pancreatitis. BMJ case reports, 2015.
Gebhardt, S., Haberhausen, M., Heinzel-Gutenbrunner, M., Gebhardt, N., Remschmidt, H., Krieg, J.-C., Hebebrand, J. & Theisen, F.M. (2009) Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course. J Psychiatr Res, 43, 620-626.
Ghanizadeh, A., Rezaee, Z., Dehbozorgi, S., Berk, M. & Akhondzadeh, S. (2014) Lovastatin for the adjunctive treatment of schizophrenia: a preliminary randomized double-blind placebo-controlled trial. Psychiatry Res, 219, 431-435.
Girault, E.M., Guigas, B., Alkemade, A., Foppen, E., Ackermans, M.T., la Fleur, S.E., Fliers, E. & Kalsbeek, A. (2014) Chronic treatment with olanzapine increases adiposity by changing fuel substrate and causes desensitization of the acute metabolic side effects. Naunyn Schmiedebergs Arch Pharmacol, 387, 185-195.
Gothelf, D., Falk, B., Singer, P., Kairi, M., Phillip, M., Zigel, L., Poraz, I., Frishman, S., Constantini, N., Zalsman, G., Weizman, A. & Apter, A. (2002) Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. Am J Psychiatry, 159, 1055-1057.
Goudie, A.J., Smith, J. & Halford, J. (2002) Characterization of olanzapine-induced weight gain in rats. J Psychopharmacol, 16, 291-296.
Han, W., Li, J., Tang, H. & Sun, L. (2017) Treatment of obese asthma in a mouse model by simvastatin is associated with improving dyslipidemia and decreasing leptin level. Biochem Biophys Res Commun, 484, 396-402.
Hoeke, G., Wang, Y., van Dam, A.D., Mol, I.M., Gart, E., Klop, H.G., van den Berg, S.M., Pieterman, E.H., Princen, H.M.G., Groen, A.K., Rensen, P.C.N., Berbee, J.F.P. & Boon, M.R. (2017) Atorvastatin accelerates clearance of lipoprotein remnants generated by activated brown fat to further reduce hypercholesterolemia and atherosclerosis. Atherosclerosis, 267, 116-126.
Humphries, S.E., Cooper, J., Dale, P., Ramaswami, U. & Group, F.H.P.R.S. (2018) The UK Paediatric Familial Hypercholesterolaemia Register: Statin-related safety and 1-year growth data. J Clin Lipidol, 12, 25-32.
Kristof, E., Doan-Xuan, Q.M., Sarvari, A.K., Klusoczki, A., Fischer-Posovszky, P., Wabitsch, M., Bacso, Z., Bai, P., Balajthy, Z. & Fesus, L. (2016) Clozapine modifies the differentiation program of human adipocytes inducing browning. Transl Psychiatry, 6, e963.
Lian, J., Huang, X.F., Pai, N. & Deng, C. (2014) Preventing olanzapine-induced weight gain using betahistine: a study in a rat model with chronic olanzapine treatment. PLoS One, 9, e104160.
Liu, X., Lian, J., Hu, C.H. & Deng, C. (2015) Betahistine co-treatment ameliorates dyslipidemia induced by chronic olanzapine treatment in rats through modulation of hepatic AMPKalpha-SREBP-1 and PPARalpha-dependent pathways. Pharmacol Res, 100, 36-46.
Meng, W., Liang, X., Chen, H., Luo, H., Bai, J., Li, G., Zhang, Q., Xiao, T., He, S., Zhang, Y., Xu, Z., Xiao, B., Liu, M., Hu, F. & Liu, F. (2017) Rheb Inhibits Beiging of White Adipose Tissue via PDE4D5-Dependent Downregulation of the cAMP-PKA Signaling Pathway. Diabetes, 66, 1198-1213.
Mund, R.A. & Frishman, W.H. (2013) Brown adipose tissue thermogenesis: beta3-adrenoreceptors as a potential target for the treatment of obesity in humans. Cardiol Rev, 21, 265-269.
Ojala, K., Repo-Tiihonen, E., Tiihonen, J. & Niskanen, L. (2008) Statins are effective in treating dyslipidemia among psychiatric patients using second-generation antipsychotic agents. J Psychopharmacol, 22, 33-38.
Petrovic, N., Walden, T.B., Shabalina, I.G., Timmons, J.A., Cannon, B. & Nedergaard, J. (2010) Chronic peroxisome proliferator-activated receptor gamma (PPARgamma) activation of epididymally derived white adipocyte cultures reveals a population of thermogenically competent, UCP1-containing adipocytes molecularly distinct from classic brown adipocytes. J Biol Chem, 285, 7153-7164.
Radaelli, G., Sausen, G., Cesa, C.C., Santos, F.S., Portal, V.L., Neyeloff, J.L. & Pellanda, L.C. (2018) Statin Treatments And Dosages In Children With Familial Hypercholesterolemia: Meta-Analysis. Arq Bras Cardiol, 111, 810-821.
Seale, P., Kajimura, S., Yang, W., Chin, S., Rohas, L.M., Uldry, M., Tavernier, G., Langin, D. & Spiegelman, B.M. (2007) Transcriptional control of brown fat determination by PRDM16. Cell Metab, 6, 38-54.
Seeman, M.V. (2009) Secondary effects of antipsychotics: women at greater risk than men. Schizophr Bull, 35, 937-948.
Shafiq, N., Bhasin, B., Pattanaik, S., Pandhi, P., Venkateshan, S.P., Singh, M. & Malhotra, S. (2007) A meta-analysis to evaluate the efficacy of statins in children with familial hypercholesterolemia. Int J Clin Pharmacol Ther, 45, 548-555.
Spertus, J., Horvitz-Lennon, M., Abing, H. & Normand, S.L. (2018) Risk of weight gain for specific antipsychotic drugs: a meta-analysis. NPJ Schizophr, 4, 12.
Stein, E.A. (2007) Statins and children: whom do we treat and when? Circulation, 116, 594-595.
Tek, C., Kucukgoncu, S., Guloksuz, S., Woods, S.W., Srihari, V.H. & Annamalai, A. (2016) Antipsychotic-induced weight gain in first-episode psychosis patients: a meta-analysis of differential effects of antipsychotic medications. Early Interv Psychiatry, 10, 193-202.
Treuer, T., Pendlebury, J., Lockman, H., Bushe, C., Karagianis, J., Raskin, J. & Lipkovich, I. (2011) Weight Gain Risk Factor assessment checklist: overview and recommendation for use. Neuroendocrinol Lett, 32, 199-205.
Weir, G., Ramage, L.E., Akyol, M., Rhodes, J.K., Kyle, C.J., Fletcher, A.M., Craven, T.H., Wakelin, S.J., Drake, A.J., Gregoriades, M.L., Ashton, C., Weir, N., van Beek, E.J.R., Karpe, F., Walker, B.R. & Stimson, R.H. (2018) Substantial Metabolic Activity of Human Brown Adipose Tissue during Warm Conditions and Cold-Induced Lipolysis of Local Triglycerides. Cell Metab, 27, 1348-1355 e1344.
Weston-Green, K., Huang, X.F. & Deng, C. (2010) Sensitivity of the female rat to olanzapine-induced weight gain-Far from the clinic? Schizophrenia research, 116, 299-300.
Weston-Green, K., Huang, X.F. & Deng, C. (2011) Olanzapine treatment and metabolic dysfunction: a dose response study in female Sprague Dawley rats. Behav Brain Res, 217, 337-346.
Yao, X., Shan, S., Zhang, Y. & Ying, H. (2011) Recent progress in the study of brown adipose tissue. Cell Biosci, 1, 35.
Zhang, Q., Lian, J., He, M., Deng, C., Wang, H. & Huang, X.F. (2014) Olanzapine reduced brown adipose tissue thermogenesis and locomotor activity in female rats. Prog Neuropsychopharmacol Biol Psychiatry, 51, 172-180.